# Effect of Crestor (Rosuvastatin) on Lipid Levels in Patients With Metabolic Syndrome

> **NCT00815659** · PHASE4 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 97 (actual)

## Conditions studied

- Metabolic Syndrome

## Interventions

- **DRUG:** rosuvastatin

## Key facts

- **NCT ID:** NCT00815659
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12
- **Primary completion:** 2010-03
- **Final completion:** 2010-03
- **Target enrollment:** 97 (ACTUAL)
- **Last updated:** 2011-08-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00815659

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00815659, "Effect of Crestor (Rosuvastatin) on Lipid Levels in Patients With Metabolic Syndrome". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00815659. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*